Experienced investor and operator focused on growth-stage technology companies, with expertise in scaling product, go-to-market and capital strategy. Brian Distler combines hands-on operating experience with board-level oversight, advising CEOs on customer acquisition, unit economics and fundraising. Frequently active in SaaS and fintech investable opportunities, the profile emphasizes capital allocation, KPIs-driven performance improvement and preparation for late-stage rounds or strategic exit.
Experienced investor and operator focused on growth-stage technology companies, with expertise in scaling product, go-to-market and capital strategy. Brian Distler combines hands-on operating experience with board-level oversight, advising CEOs on customer acquisition, unit economics and fundraising. Frequently active in SaaS and fintech investable opportunities, the profile emphasizes capital allocation, KPIs-driven performance improvement and preparation for late-stage rounds or strategic exit.
Targets growth-stage technology companies, primarily SaaS and fintech, deploying capital to scale repeatable revenue models and optimize unit economics. Investment decisions prioritize KPIs-driven underwriting—CAC/LTV, retention, gross margins—and milestone-based follow-on reserves to preserve capital efficiency. Prefers founder-led teams where operating partnership and board governance can accelerate go-to-market and product scaling. Time horizon focused on late-stage rounds or strategic exits (18–36 months), with a disciplined risk framework that favors predictable revenue, margin expansion, and measurable customer acquisition leverage.
Targets growth-stage technology companies, primarily SaaS and fintech, deploying capital to scale repeatable revenue models and optimize unit economics. Investment decisions prioritize KPIs-driven underwriting—CAC/LTV, retention, gross margins—and milestone-based follow-on reserves to preserve capital efficiency. Prefers founder-led teams where operating partnership and board governance can accelerate go-to-market and product scaling. Time horizon focused on late-stage rounds or strategic exits (18–36 months), with a disciplined risk framework that favors predictable revenue, margin expansion, and measurable customer acquisition leverage.
| Trades 1448 | Longs Won 1130/1448 78% | Profit Factor 23.14 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $237,812.25 |
| Average Win $64,661.1 | Best Trade (Aug 28) $5.81M | Sharpe Ratio -11.84 |
| Average Loss -$9,930.5 | Worst Trade (Sep 01) -$388,192.08 | Z-Score 26.1 (100%) |
| Commissions $0 | Avg. Trade Length 1y 2m 4w | Expectancy $48,279.8 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 27,778 | 25,000 | 22,222 | 19,444 | 16,667 | 13,889 | 11,111 | 8,333 | 5,556 | 2,778 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| 2547 25470MAB5 | 12,000 | $6,438 | $6,438 | - | - | - | 0.0 |
AAPL Apple Inc. | 27,220 | $5.33M | $8.41M | - | $3.08M | 57.83% | -7.354% |
ABBV AbbVie Inc. | 2,603 | $418,308.77 | $653,196.82 | - | $234,888.05 | 56.15% | -2.513% |
ABT Abbott Laboratories | 2,475 | $276,274.95 | $261,607.5 | - | -$14,667.45 | -5.31% | +0.085% |
ADX Adams Diversified Equity Fund, Inc. | 8,003 | $204,486 | $204,236.56 | - | -$249.44 | -0.12% | +1.27% |
ALL Allstate Corporation | 1,013 | $241,001 | $267,513.03 | - | $26,512.03 | 11% | -0.49% |
AMAT Applied Materials, Inc. | 301 | $217,656 | $152,808.67 | - | -$64,847.33 | -29.79% | +1.176% |
AMD Advanced Micro Devices, Inc. | 616 | $357,695 | $293,308.39 | - | -$64,386.61 | -18% | -1.904% |
AMGN Amgen Inc. | 642 | $226,192.96 | $247,272.72 | - | $21,079.76 | 9.32% | -0.64% |
AMT American Tower Corporation | 1,791 | $389,721.73 | $310,487.76 | - | -$79,233.97 | -20.33% | -0.631% |
AMZN Amazon.com Inc | 10,726 | $1.84M | $2.91M | - | $1.07M | 57.94% | +15.321% |
APP AppLovin Corporation Class A Common Stock | 1,035 | $533,263 | $409,756.49 | - | -$123,506.51 | -23.16% | -1.973% |
AVDE Avantis International Equity ETF | 70,736 | $4.64M | $6.45M | - | $1.81M | 39.14% | -0.458% |
AVEM Avantis Emerging Markets Equity ETF | 59,352 | $4.2M | $5.31M | - | $1.11M | 26.51% | +0.101% |
AVGO Broadcom Inc. | 1,549 | $473,892.43 | $602,994.72 | - | $129,102.29 | 27.24% | +0.371% |
AVUS Avantis U.S. Equity ETF | 110,978 | $11.09M | $14.16M | - | $3.07M | 27.64% | +0.567% |
AVY Avery Dennison Corporation | 2,006 | $401,054.44 | $340,478.38 | - | -$60,576.06 | -15.1% | -2.912% |
AZN AstraZeneca PLC American Depositary Shares | 1,056 | $208,213.62 | $179,139.84 | - | -$29,073.78 | -13.96% | -0.992% |
BAC Bank of America Corporation | 4,852 | $251,564.09 | $300,581.4 | - | $49,017.31 | 19.49% | +0.356% |
BND Vanguard Total Bond Market Index Fund | 4,770 | $345,606.85 | $344,537.1 | - | -$1,069.75 | -0.31% | -0.262% |